Symphogen A/S   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Lyngby Denmark (2000)
Status: Acquired by Servier (2020)

Organization Overview

First Clinical Trial
2008
NCT00718692
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Symphogen A/S | Symphogen A/S, Denmark